2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

mTOR kinase

" in MedChemExpress (MCE) Product Catalog:

92

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

2

Peptides

10

Natural
Products

1

Recombinant Proteins

3

Isotope-Labeled Compounds

6

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13328
    Sapanisertib
    50+ Cited Publications

    INK-128; MLN0128; TAK-228

    		 mTOR Autophagy Cancer
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib
  • HY-10422
    AZD-8055
    65+ Cited Publications

    		 mTOR Autophagy Apoptosis Cancer
    AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2 .
    AZD-8055
  • HY-10971
    Alisertib
    Maximum Cited Publications
    72 Publications Verification

    MLN 8237

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-50673
    Dactolisib
    65+ Cited Publications

    BEZ235; NVP-BEZ235

    		 PI3K mTOR Autophagy Cancer
    Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
    Dactolisib
  • HY-111373
    RapaLink-1
    10+ Cited Publications

    		 mTOR Autophagy Cancer
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
    RapaLink-1
  • HY-139609
    Camonsertib
    2 Publications Verification

    RP-3500; ATR inhibitor 4

    		 ATM/ATR mTOR Cancer
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
    Camonsertib
  • HY-15346
    Copanlisib
    30+ Cited Publications

    BAY 80-6946

    		 PI3K Apoptosis Cancer
    Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
    Copanlisib
  • HY-15346A
    Copanlisib dihydrochloride
    30+ Cited Publications

    BAY 80-6946 dihydrochloride

    		 PI3K Apoptosis Cancer
    Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
    Copanlisib dihydrochloride
  • HY-13246
    Apitolisib
    10+ Cited Publications

    GDC-0980; GNE 390; RG 7422

    		 PI3K mTOR Apoptosis Cancer
    Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR.
    Apitolisib
  • HY-W021448
    Glycocyamine
    1 Publications Verification

    Guanidinoacetic acid

    		 Endogenous Metabolite Metabolic Disease
    Glycocyamine (Guanidinoacetic acid) is a direct precursor of creatine and an orally active energy metabolism regulator and myogenic differentiation inducer. Glycocyamine can activate the Akt/mTOR/S6K signaling pathway via miR-133a-3p and miR-1a-3p, and stimulate the mRNA expression of myogenic differentiation factor 1 (MyoD) and myopoietin (MyoG). Glycocyamine can increase muscle creatine concentration and maintain ATP homeostasis through the creatine phosphate/creatine kinase system. Glycocyamine can be used in research on feed additives for poultry farming .
    Glycocyamine
  • HY-16962
    CC-115
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115
  • HY-10423
    OSI-027
    10+ Cited Publications

    ASP7486

    		 mTOR Autophagy Cancer
    OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively .
    OSI-027
  • HY-16956
    Onatasertib
    3 Publications Verification

    CC-223; ATG-008

    		 mTOR Apoptosis Cancer
    Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.
    Onatasertib
  • HY-100398
    PF-04979064
    2 Publications Verification

    		 PI3K mTOR Cancer
    PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with Kis of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.
    PF-04979064
  • HY-N0281
    Daphnetin
    Maximum Cited Publications
    7 Publications Verification

    7,8-Dihydroxycoumarin

    		 EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite Cardiovascular Disease Inflammation/Immunology Cancer
    Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC50s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .
    Daphnetin
  • HY-16397
    Phenformin
    5+ Cited Publications

    Phenethylbiguanide

    		 Mitochondrial Metabolism AMPK Apoptosis Autophagy mTOR Neurological Disease Metabolic Disease Cancer
    Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .
    Phenformin
  • HY-10372
    PP121
    4 Publications Verification

    		 mTOR PDGFR VEGFR Src Apoptosis Cancer
    PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.
    PP121
  • HY-15174
    Dactolisib Tosylate
    65+ Cited Publications

    BEZ235 Tosylate; NVP-BEZ 235 Tosylate

    		 PI3K mTOR Autophagy Cancer
    Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
    Dactolisib Tosylate
  • HY-126077
    MTI-31
    1 Publications Verification

    LXI-15029

    		 mTOR Inflammation/Immunology Cancer
    MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .
    MTI-31
  • HY-175751
    LRK-4189

    		mTOR Cancer
    LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
    LRK-4189
  • HY-N0712
    Typhaneoside
    3 Publications Verification

    		 Autophagy mTOR Akt FXR Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .
    Typhaneoside
  • HY-16585
    VS-5584
    5 Publications Verification

    SB2343

    		 PI3K mTOR Cancer
    VS-5584 is a pan-PI3K/mTOR kinase inhibitor with IC50s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.
    VS-5584
  • HY-10044
    WYE-132
    4 Publications Verification

    WYE-125132

    		 mTOR Apoptosis Cancer
    WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.
    WYE-132
  • HY-10811
    GNE-493
    2 Publications Verification

    		 PI3K mTOR Cancer
    GNE-493 is a potent, selective, and orally available dual pan-PI3-kinase/mTOR inhibitor with IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.
    GNE-493
  • HY-16962A
    CC-115 hydrochloride
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115 hydrochloride
  • HY-124760
    hSMG-1 inhibitor 11e
    3 Publications Verification

    		 mTOR PI3K CDK Cancer
    hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM) .
    hSMG-1 inhibitor 11e
  • HY-136265
    BC-LI-0186
    1 Publications Verification

    		 Aminoacyl-tRNA Synthetase Cancer
    BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
    BC-LI-0186
  • HY-W338584
    Hydroxycitric acid tripotassium
    1 Publications Verification

    		 Keap1-Nrf2 Ferroptosis Apoptosis mTOR NF-κB ATP Citrate Lyase AMPK Ribosomal S6 Kinase (RSK) DNA/RNA Synthesis Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation .
    Hydroxycitric acid tripotassium
  • HY-139534
    ARI-1
    1 Publications Verification

    		 ROR Apoptosis Akt mTOR PARP Cancer
    ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor. ARI-1 blocks the PI3K/AKT/mTOR signaling pathway in a ROR1-dependent manner. ARI-1 upregulates cleaved-PARP and p-P38. ARI-1 induces Apoptosis. ARI-1 has anticancer activity against non-small cell lung cancer .
    ARI-1
  • HY-131972
    PF-06843195

    		PI3K Cancer
    PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .
    PF-06843195
  • HY-N1745A
    3-Deoxysappanchalcone
    2 Publications Verification

    		 Influenza Virus Infection Inflammation/Immunology Cancer
    3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .
    3-Deoxysappanchalcone
  • HY-137978
    Ezurpimtrostat
    3 Publications Verification

    GNS561

    		 SARS-CoV IFNAR Autophagy Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
    Ezurpimtrostat
  • HY-124652
    TBK1/IKKε-IN-4

    		IKK Cancer
    TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC50 values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR .
    TBK1/IKKε-IN-4
  • HY-N6841
    Rhodiolin
    1 Publications Verification

    		 Glucose-6-Phosphate Isomerase (GPI) Casein Kinase Virus Protease Flavivirus PI3K Akt mTOR Apoptosis Infection Cancer
    Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral .
    Rhodiolin
  • HY-153120A
    PI3K/mTOR Inhibitor-13 sodium

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
    PI3K/mTOR Inhibitor-13 sodium
  • HY-10620
    PI3K-IN-22

    		PI3K mTOR Cancer
    PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC50s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .
    PI3K-IN-22
  • HY-162143
    SKI-349

    		SphK Akt mTOR Cancer
    SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .
    SKI-349
  • HY-P10323
    T7 Peptide

    Tumstatin (74-98), human

    		 Integrin FAK mTOR Apoptosis Cancer
    T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
    T7 Peptide
  • HY-P10323A
    T7 Peptide TFA

    Tumstatin (74-98), human TFA

    		 Integrin FAK mTOR Apoptosis Cancer
    T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
    T7 Peptide TFA
  • HY-W348485
    WRX606

    		mTOR Cancer
    WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC50 = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50 = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent .
    WRX606
  • HY-15268
    PP487

    		c-Met/HGFR PI3K DNA-PK mTOR Bcr-Abl Src VEGFR EGFR PDGFR Cancer
    PP487 is a selective dual inhibitor of Tyrosine kinase/PI3-K, with IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. PP487 can be used in cancer research .
    PP487
  • HY-161509
    PT-88

    		mTOR Cancer
    PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC50=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the study of breast cancer .
    PT-88
  • HY-15174R
    Dactolisib Tosylate (Standard)

    BEZ235 Tosylate (Standard); NVP-BEZ 235 Tosylate (Standard)

    		 PI3K mTOR Autophagy Reference Standards Cancer
    Dactolisib (Tosylate) (Standard) is the analytical standard of Dactolisib (Tosylate). This product is intended for research and analytical applications. Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
    Dactolisib Tosylate (Standard)
  • HY-164460
    AZD1897

    		Pim Cancer
    AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .
    AZD1897
  • HY-164384
    DFX117

    		PI3K Akt mTOR Apoptosis Cancer
    DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC50s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .
    DFX117
  • HY-W021448S
    Glycocyamine-d2

    Guanidinoacetic acid-d2

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Glycocyamine-d2 (Guanidinoacetic acid-d2) is the deuterium labeled Glycocyamine (HY-W021448). Glycocyamine is a direct precursor of creatine and an orally active energy metabolism regulator and myogenic differentiation inducer. Glycocyamine can activate the Akt/mTOR/S6K signaling pathway via miR-133a-3p and miR-1a-3p, and stimulate the mRNA expression of myogenic differentiation factor 1 (MyoD) and myopoietin (MyoG). Glycocyamine can increase muscle creatine concentration and maintain ATP homeostasis through the creatine phosphate/creatine kinase system. Glycocyamine can be used in research on feed additives for poultry farming.
    Glycocyamine-d2
  • HY-W021448S1
    Glycocyamine-15N,13C2

    Guanidinoacetic acid-15N,13C2

    		 Endogenous Metabolite Metabolic Disease
    Glycocyamine- 15N, 13C2 (Guanidinoacetic acid- 15N, 13C2) is the 13C and 15N labeled Glycocyamine (HY-W021448) . Clycocyamine is a direct precursor of creatine and an orally active energy metabolism regulator and myogenic differentiation inducer. Glycocyamine can activate the Akt/mTOR/S6K signaling pathway via miR-133a-3p and miR-1a-3p, and stimulate the mRNA expression of myogenic differentiation factor 1 (MyoD) and myopoietin (MyoG). Glycocyamine can increase muscle creatine concentration and maintain ATP homeostasis through the creatine phosphate/creatine kinase system. Glycocyamine can be used in research on feed additives for poultry farming.
    Glycocyamine-15N,13C2
  • HY-153120
    PI3K/mTOR Inhibitor-13

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
    PI3K/mTOR Inhibitor-13
  • HY-10971A
    Alisertib sodium

    MLN 8237 sodium

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-123849
    SN32976

    		PI3K mTOR Cancer
    SN32976 is a potent and selective class I PI3K and mTOR inhibitor with IC50s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .
    SN32976

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: